BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38547126)

  • 1. Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion.
    Ye F; Yuan Z; Tang Y; Li J; Liu X; Sun X; Chen S; Ye X; Zeng Z; Zhang XK; Zhou H
    Cell Rep; 2024 Apr; 43(4):114002. PubMed ID: 38547126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
    Zoratti GL; Tanabe LM; Hyland TE; Duhaime MJ; Colombo É; Leduc R; Marsault E; Johnson MD; Lin CY; Boerner J; Lang JE; List K
    Oncotarget; 2016 Sep; 7(36):58162-58173. PubMed ID: 27528224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).
    Carpenter BL; Chen M; Knifley T; Davis KA; Harrison SMW; Stewart RL; O'Connor KL
    J Biol Chem; 2015 Nov; 290(45):27228-27238. PubMed ID: 26381405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
    Zoratti GL; Tanabe LM; Varela FA; Murray AS; Bergum C; Colombo É; Lang JE; Molinolo AA; Leduc R; Marsault E; Boerner J; List K
    Nat Commun; 2015 Apr; 6():6776. PubMed ID: 25873032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation.
    Ye F; Chen S; Liu X; Ye X; Wang K; Zeng Z; Su Y; Zhang XK; Zhou H
    J Cell Mol Med; 2019 Jan; 23(1):155-166. PubMed ID: 30370662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
    Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
    Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hepatocyte growth factor regulatory factors in human breast cancer.
    Parr C; Watkins G; Mansel RE; Jiang WG
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
    Fang JD; Lee SL
    Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion.
    Johnson H; Lescarbeau RS; Gutierrez JA; White FM
    J Proteome Res; 2013 Apr; 12(4):1856-67. PubMed ID: 23438512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
    Gray K; Elghadban S; Thongyoo P; Owen KA; Szabo R; Bugge TH; Tate EW; Leatherbarrow RJ; Ellis V
    Thromb Haemost; 2014 Aug; 112(2):402-11. PubMed ID: 24696092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LPA, HGF, and EGF utilize distinct combinations of signaling pathways to promote migration and invasion of MDA-MB-231 breast carcinoma cells.
    Harrison SM; Knifley T; Chen M; O'Connor KL
    BMC Cancer; 2013 Oct; 13():501. PubMed ID: 24160245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells.
    Kawase N; Sugihara A; Kajiwara K; Hiroshima M; Akamatsu K; Nada S; Matsumoto K; Ueda M; Okada M
    J Biol Chem; 2022 Mar; 298(3):101630. PubMed ID: 35085554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
    Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
    Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
    Szabo R; Rasmussen AL; Moyer AB; Kosa P; Schafer JM; Molinolo AA; Gutkind JS; Bugge TH
    Oncogene; 2011 Apr; 30(17):2003-16. PubMed ID: 21217780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
    Nishimura Y; Yoshioka K; Bereczky B; Itoh K
    Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
    Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL
    Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulated activation of matriptase in breast cancer cells.
    Benaud CM; Oberst M; Dickson RB; Lin CY
    Clin Exp Metastasis; 2002; 19(7):639-49. PubMed ID: 12498394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis.
    Yamasaki K; Mukai S; Nagai T; Nakahara K; Fujii M; Terada N; Ohno A; Sato Y; Toda Y; Kataoka H; Kamoto T
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
    Mukai S; Yamasaki K; Fujii M; Nagai T; Terada N; Kataoka H; Kamoto T
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.